Top Stock Reports for Tesla, Adobe & Merck
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Adobe Inc. (ADBE), and Merck & Co., Inc. (MRK).
Thursday, December 23, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Adobe Inc. (ADBE), and Merck & Co., Inc. (MRK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Tesla have outperformed the Zacks Domestic Automotive industry over the past year (+52.4% vs. +19.5%). The Zacks analyst believes that robust demand for Models 3 and Y has been buoying Tesla's revenues. TSLA achieved record levels of production and deliveries, despite a chip crunch, in the third quarter of 2021.
Tesla has also started ramping up volumes of Models S and X. China, being the biggest EV market, means Tesla's Shanghai factory is buoying its revenue prospects. Steadily increasing automotive as well as energy generation and storage revenues have also been boosting earnings prospects.
Adobe shares have gained +12.7% in the year to date period against the Zacks Software industry’s gain of +39.1%; however, things seem to be improving. The Zacks analyst believes that Adobe’s Creative Cloud, Document Cloud and Adobe Experience Cloud products drove top-line growth in the fiscal fourth quarter.
Growth in emerging markets, robust online video creation demand, solid adoption of Acrobat and improving average revenue per user are some of the major tailwinds. Adobe’s dominant market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and strong Workfront momentum are likely to boost its prospects in the quarters ahead. Low end-market demand and high acquisition expenses remain as concerns though.
Shares of Merck have gained +1.6% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +18.2%, but things are likely to improve. The Zacks analyst believes that key drugs like Keytruda, Lynparza and Bridion have been driving Merck’s sales.
Continued uptake in lung cancer and increasing usage in other cancer indications have been driving Keytruda’s sales. Animal health and vaccine products remain as core growth drivers. Generic competition for several of Merck’s drugs as well as rising competitive pressure, primarily on the diabetes franchise, remain as major concerns though.
Other noteworthy reports we are featuring today include Edwards Lifesciences Corp. (EW), Enbridge Inc. (ENB) and Norfolk Southern Corp. (NSC).
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Zacks’ Top Picks to Cash in on Artificial Intelligence
This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Norfolk Southern Corporation (NSC): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Adobe Inc. (ADBE): Free Stock Analysis Report
Enbridge Inc (ENB): Free Stock Analysis Report
Tesla, Inc. (TSLA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research